Skip to main content


Subcutaneous therapy in the home setting

Subcutaneous therapy in the home setting in immunodeficiency, types of anaemia requiring blood transfusions, autoimmunity and pain

About subcutaneous infusion therapy 

Subcutaneous delivery of immunoglobulins has been used successfully for almost 30 years(1, 2). The subcutaneous method offers a number of advantages over intravenous administration, including:  

  • Achieving equivalent IgG levels(3)  
  • Improved quality of life(4)  
  • Less pressure on healthcare resources 

Patients do not need to attend hospital and can adapt the therapy to their everyday lives. Most patients who have tried out the method in the home setting prefer to carry on with home therapy(4).  Subcutaneous therapy with immunoglobulins at home is convenient, effective and safe(5).


Nordic Infucare offers support and service for at-home therapy. Our product specialists have many years of experience in the field and monitor the whole procedure with planning, instruction and follow-up for healthcare and, where required, training of patients.  


Our portable infusion pumps are specially adapted for subcutaneous administration of medicines for example in primary and secondary immunodeficiency, types of anaemia requiring blood transfusions, such as thalassaemia, in autoimmune conditions with neurological symptoms such as CIDP and in pain therapy.   

Read more about the subcutaneous method, the advantages it offers and how to get started.

If you would like to know how we can make work easier for your clinic and help you choose the right aids for your patients, talk to us at Nordic Infucare.

Contact us via our contact forms. We always reply within 24 hours, and usually the same day.

Subcutaneous drug therapy 

Administering medication subcutaneously offers a number of advantages over intravenous infusion. The method is easy to use, and patients are able to deal with their own drug therapy at home.  

1. Gardulf et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92:200-204 

2. Gardulf et al. 1995. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet, vol 345, feb 11, 1995 

3. Chapel et al. The Comparison of the Efficacy and Safety of Intravenous Versus  Subcutaneous Immunoglobulin. Replacement Therapy, Journal of Clinical Immunology, Vol. 20, No. 2, 2000) 

4. Gardulf et al. Immunoglobulin Treatment for Primary Antibody Deficiencies - Advantages of the Subcutaneous Route. Biodrugs 2007; 21 (2): 105-116 THERAPY REVIEW) 

5. Markvardsen et al, Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology 2013).